Search results
Results from the WOW.Com Content Network
Glipizide. Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1][2] It is used together with a diabetic diet and exercise. [1][2] It is not indicated for use by itself in type 1 diabetes. [1][2] It is taken by mouth. [1][2] Effects generally begin ...
Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. [7] It is used when dietary changes, exercise, and weight loss are not enough. [4] It is taken by mouth.
Diabetes medication. Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic ...
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes. [1][2] It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy. [1] Use of glimepiride is recommended in conjunction with lifestyle modifications such ...
Glibenclamide, also known as glyburide, is an antidiabetic medication used to treat type 2 diabetes. [1] It is recommended that it be taken together with diet and exercise. [1] It may be used with other antidiabetic medication. [1] It is not recommended for use by itself in type 1 diabetes. [1] It is taken by mouth.
However, short metabolic half-life due to oxidation of the A-ring phenyl group was problematic. At first, the researchers tried to make a fluorinated derivative. The derivative showed improved metabolic stability and excellent inhibition of the DPP-4 enzyme. However, it was also found to inhibit CYP 450 3A4 and block the hERG channel
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
Native GLP-1 is a peptide hormone with a half-life of 2 minutes because it is rapidly cleared by the enzyme dipeptidyl peptidase-4. [27] As a result, different GLP-1 agonist drugs are modified in various ways to extend the half-life, resulting in drugs that can be dosed multiple times per day, daily, weekly, or even less often. [27]